Related Experiment Videos
Association of SCARB1 Polymorphisms with Coronary Artery Disease Risk: A Systematic Review and Meta-Analysis
Jinzhou Yu1, Qianyu Zhou2, Qiang Zhang1
1School of Nursing and Health, Zhengzhou University, Zhengzhou 450001, China.
Insights
Genetic variants in the SCARB1 gene, specifically rs5888 and rs10846744, show potential links to coronary artery disease (CAD) risk. rs5888 is associated with lower CAD risk in males, while rs10846744 suggests a protective effect.
Area of Science:
- Genetics
- Cardiovascular Disease Research
- Molecular Biology
Background:
- Coronary artery disease (CAD) is a leading global health concern.
- The lipid metabolism gene SCARB1 is implicated in CAD susceptibility, but evidence is conflicting.
- Investigating SCARB1 polymorphisms offers insight into CAD risk factors.
Purpose of the Study:
- To systematically evaluate the association between SCARB1 gene polymorphisms and CAD risk.
- To clarify the role of specific SCARB1 variants (rs5888, rs4238001, rs10846744) in CAD development.
- To explore potential sex-specific or ethnicity-based differences in these associations.
Main Methods:
- Systematic literature search of major databases (PubMed, Embase, etc.) up to February 2026.
- Inclusion of 12 case-control studies with 3947 CAD cases and 5076 controls.
- Meta-analysis of SCARB1 polymorphisms (rs5888, rs4238001, rs10846744) using various genetic models and heterogeneity assessment (I²).
Main Results:
- SCARB1 rs5888 showed no overall association with CAD, but a significantly lower risk in males with the TT genotype (OR=0.73).
- No significant association was found for rs4238001 with CAD across all models.
- SCARB1 rs10846744 demonstrated a significant inverse association with CAD risk (allelic OR=0.78, dominant OR=0.68).
Conclusions:
- SCARB1 rs5888 exhibits a male-specific association with reduced CAD risk.
- SCARB1 rs10846744 suggests a potentially protective role against CAD, warranting further investigation.
- These findings contribute to understanding the genetic underpinnings of CAD.
Background:
Coronary artery disease (CAD) remains a major cause of morbidity and mortality worldwide. Variants in the lipid metabolism gene SCARB1 may influence CAD susceptibility, but existing evidence is inconsistent.
Methods:
We systematically searched PubMed, Embase, Web of Science, the Cochrane Library, and Scopus up to 13 February 2026 for case-control studies on SCARB1 polymorphisms and CAD risk. Three polymorphisms, rs5888, rs4238001, and rs10846744, were included. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated under multiple genetic models. Subgroup analyses were conducted for rs5888 by sex, ethnicity, and clinical outcome. Heterogeneity was assessed using I2.
Results:
12 eligible case-control studies involving 3947 CAD cases and 5076 controls were included. Overall, rs5888 was not significantly associated with CAD in any genetic model, either in the pooled analysis or in subgroup analyses by ethnicity and clinical outcome. In sex-stratified analyses, males carrying the TT genotype had a significantly lower CAD risk under the recessive model (OR = 0.73, 95% CI: 0.57-0.93), whereas no significant association was observed in females. No significant association was found between rs4238001 and CAD under any model. In contrast, the rs10846744 G allele was significantly associated with reduced CAD risk under the allelic (OR = 0.78, 95% CI: 0.64-0.94), dominant (OR = 0.68, 95% CI: 0.50-0.93), homozygote (OR = 0.65, 95% CI: 0.44-0.94), and additive models (OR = 0.80, 95% CI: 0.67-0.96).
Conclusions:
SCARB1 rs5888 showed a male-specific association with CAD, while rs10846744 showed a suggestive inverse association that requires further validation.
Related Concept Videos
Coronary Artery Disease I: Introduction
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Coronary Artery Disease IV: Preventive Measures
Single Nucleotide Polymorphisms-SNPs
Atherosclerosis III: Management